Challenges of measuring accurate estradiol levels in aromatase inhibitor‐treated postmenopausal breast cancer patients on vaginal estrogen therapy

Breast cancer patients who are taking adjuvant Aromatase Inhibitor (AI) therapy typically have extremely low estradiol levels, which are undetectable by routine clinical laboratories. Thus, it becomes difficult to assess the safety of interventions such as low‐dose vaginal estrogen, which may increa...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Pharmacol Res Perspect
Asıl Yazarlar: Niravath, Polly, Bhat, Raksha, Al‐Ameri, Mohamed, AlRawi, Ahmed, Foreman, Claudette, Trivedi, Meghana V.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2017
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5684855/
https://ncbi.nlm.nih.gov/pubmed/28805983
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.330
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller